Based on our analysis of emerging evidence, the following changes have been made:
- Evidence has been found that donepezil (Aricept®), which is prescribed for dementia (Alzheimer’s disease) is associated with Torsades de Pointes (TdP). Consequently, we have added it to the list of drugs with Known Risk of TdP.
- We have also added cilostazol (Pletal®), a drug for treatment of intermittent claudication, to the list of drugs with Known Risk of TdP.
- Upon review, we have determined that the diuretic torsemide (Demadex® and other brands), as with furosemide (Lasix®), can prolong QT by causing low serum magnesium and/or low serum potassium – both conditions associated with TdP. Therefore, it has been added to the list of drugs with Conditional Risk of TdP.
- We have found that atomoxetine (Strattera®), an adrenergic drug for ADHD that is currently on the list of Drugs to Be Avoided for patients with congenital long QT syndrome, has the ability to prolong QT interval. For this reason, it has now also been added to the list of drugs with Possible Risk of TdP.
In addition to atomoxetine, all drugs listed above are on the list of Drugs to Be Avoided for patients with congenital LQTS.